BioSpace News Archive

Business

Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix® in highly sensitized kidney transplant patients

Hansa Biopharma AB today announced that the Polish Ministry of Health has agreed to include Idefirix® on its reimbursement list for desensitization of highly sensitized patients prior to kidney transplantation.

August 22, 2022
·
8 min read
Pharm Country

Bayer to Present Data From Cardiovascular Portfolio, Including a Late-Breaking Presentation From FIDELITY for KERENDIA® (finerenone) and New Phase IIb Data From PACIFIC Trial Program for the Oral Factor XIa Inhibitor asundexian

Bayer to Present Data From Cardiovascular Portfolio, Including a Late-Breaking Presentation From FIDELITY for KERENDIA ® (finerenone) and New Phase IIb Data From PACIFIC Trial Program for the Oral Factor XIa Inhibitor asundexian.

August 22, 2022
·
12 min read
Business

Maximilian Doebler Appointed Chief Business Officer of HMNC Brain Health

HMNC Brain Health announced the appointment of Dr. Maximilian Doebler, previous Head of Business Development & Licensing of HMNC Brain Health, as Chief Business Officer.

August 22, 2022
·
2 min read
Biotech Bay

180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company announced that the first patient has been randomized in the clinical trial to evaluate anti-tumor necrosis factor (TNF) for patients with early-stage, pain predominant frozen shoulder.

August 22, 2022
·
10 min read
Drug Development

Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing’s Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, announces the addition of the Mayo Clinic to its open-label Phase 1/2 trial with seclidemstat in Ewing’s sarcoma and FET-rearranged sarcomas.

August 22, 2022
·
7 min read
Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration

Veru Inc. today announced that Australia’s Therapeutic Goods Administration (TGA) has determined that sabizabulin treatment in hospitalized COVID-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS) qualifies for an expedited, provisional registration regulatory pathway.

August 22, 2022
·
10 min read
Drug Development

DynamiCure Announces IND Clearance to Advance First Antibody Candidate from its DC-6001 Anti-CD93 Program into Clinical Development

DynamiCure today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to advance the first monoclonal antibody candidate from the company’s DC-6001 anti-CD93 development program into a Phase 1 study ( NCT05496595 ).

August 22, 2022
·
3 min read
Biotech Bay

ABVC Provides Oncology Pipeline Updates

ABVC BioPharma, Inc. today provided an update on its development of oncology medicines for the treatment pancreatic cancer (ABV-1703), non-small cell lung cancer (ABV-1519).

August 22, 2022
·
5 min read
TC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference

TC Biopharm today announced that Chief Executive Officer, Bryan Kobel will present a company overview at the H.C. Wainwright 24th annual global investment conference.

August 22, 2022
·
2 min read
BioCapital

RegeneRx Issues 2022 Letter To Stockholders

RegeneRx Biopharmaceuticals, Inc. has issued a Letter to Stockholders updating development of product candidates.

August 22, 2022
·
2 min read